PUBLISHER: Grand View Research | PRODUCT CODE: 2151579
PUBLISHER: Grand View Research | PRODUCT CODE: 2151579
The global pharmaceutical manufacturing market size was valued at USD 616.1 billion in 2025 and is projected to grow from USD 664.0 billion in 2026 to USD 990.5 billion in 2033, at a CAGR of 5.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.2% in 2025. The market is driven by demand for advanced therapeutics, biologics, and high-volume generic drugs alongside increasing chronic disease prevalence and healthcare spending.
With more patients and advanced treatments, demand for both traditional drugs and complex biologics has been increasing significantly. This has stimulated production scale ups and capacity enhancements among manufacturers, while ensuring consistent quality, safety, and compliance with regulatory frameworks. The increasing number of drug approvals by regulatory bodies is also expected to drive growth in drug manufacturing processes. In 2025, the FDA approved 32 novel drugs, indicating a positive trend.
A major driver supporting the market is the rapid evolution of drug development technologies. Increasing adoption of biologics, biosimilars, cell and gene therapies, and personalized medicines is reshaping production requirements, prompting manufacturers to invest in flexible, high-precision bioprocessing systems. At the same time, the shift toward continuous manufacturing and automation is helping companies reduce operational costs, optimize output, and improve product reliability, all of which are essential for meeting the rising global demand.
Global Pharmaceutical Manufacturing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmaceutical manufacturing market report based on molecule, drug development, formulation, route of administration, therapy area, prescription, age group, sales channel, and region:
Biologics & Biosimilars (Large Molecules)
Conventional Drugs (Small Molecules)
In-house
Outsource
Tablets
Capsules
Injectable
Sprays
Suspensions
Powders
Other Formulations
Oral
Topical
Parenteral
Inhalations
Other Routes of Administration
Cardiovascular Diseases (CVDs)
Pain
Diabetes
Cancer
Respiratory Diseases
Other Diseases
Prescription Medicines
Over-the-counter (OTC) Medicines
Children & Adolescents
Adults
Geriatric
Retail
Non-retail
North America
Europe
Asia Pacific
Latin America
Middle East and Africa